New research shows adults aged 35 to 64 prescribed gabapentin for chronic pain are twice as likely to develop dementia and ...

Researchers have observed a mechanism in the brain that may ‘pump the brakes’ on acute pain to prevent overload while not inhibiting chronic pain at all.

Studies are now underway that could help Journavx win additional FDA approvals for some kinds of chronic pain. Vertex says it is specifically studying Journavx in patients with diabetic peripheral ...

In a small Phase 2 study presented at the 53rd American Society of Hematology's Annual Meeting and Exposition, once-daily prasugrel 5mg for 30 days showed some promise of decreasing pain in ...

It's a pill for severe acute pain that works by blocking plain signals from where someone hurts. It's offered hope for the 1 in 5 Americans who suffer from chronic pain, but it's also just out of ...

It's offered hope for the 1 in 5 Americans who suffer from chronic pain, but it's also just out of reach. Journavx is the first new kind of painkiller in more than 20 years, and the medical ...

Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet.